Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults |
| |
| Authors: | Treanor John J Schiff Gilbert M Couch Robert B Cate Thomas R Brady Rebecca C Hay C Mhorag Wolff Mark She Dewei Cox Manon M J |
| |
| Affiliation: | Infectious Disease Division, University of Rochester, Rochester, New York 14642, USA. john_treanor@urmc.rochester.edu |
| |
| Abstract: | BACKGROUND: Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine. METHODS: In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA. RESULTS: Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA. CONCLUSIONS: Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
